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ARTICLE OPEN
Satisfaction with a digitally-enabled telephone health coaching
intervention for people with non-diabetic hyperglycaemia
Peter Coventry 1, Peter Bower2, Amy Blakemore3, Elizabeth Baker3, Mark Hann2, Jinshuo Li4, Angela Paisley5 and Martin Gibson5
International evidence shows that lifestyle interventions can effectively reduce the risk of developing diabetes in people with non-
diabetic hyperglycaemia (NDH). A candidate intervention that has potential to be rolled out at population level is health coaching.
Digital interventions offer the means to potentially enhance user satisfaction with health coaching and improve efﬁciencies. We
used a randomised controlled trial to test whether a digitally-enabled health coaching intervention that included an online
dashboard and telephone health coaching improved user satisfaction and cost-efﬁciencies compared with a telephone only health
coaching intervention. The primary outcome was satisfaction measured by Client Satisfaction Questionnaire (CSQ-8). 103
participants with NDH were allocated to the telephone coaching only intervention and 106 participants with NDH were allocated to
the digital and telephone coaching intervention. In an intention-to-treat analysis satisfaction was higher in participants allocated to
the digital and telephone coaching intervention than those allocated to the telephone only intervention, but the difference was not
signiﬁcant. There were no signiﬁcant differences between the groups on secondary outcomes (HbA1c, BMI, activation, depression,
self-management, health status). From a service commissioning perspective the mean incremental cost of the digitally-enabled
intervention was £236 ($332; €270). Call times, including administration, were longer for participants allocated to the digitally-
enabled intervention. The results show that user satisfaction with digitally-enabled intervention is broadly equivalent with that of
telephone delivered interventions in the context of routinely delivered diabetes prevention programmes. There is scope for future
work that assesses how economies of scale can be achieved at larger user bases.
npj Digital Medicine             (2019) 2:5 ; https://doi.org/10.1038/s41746-019-0080-6
INTRODUCTION
Diabetes is a major global public health threat affecting nearly half
a billion adults.1 Over 90% of cases are type 2 diabetes which
develops in the presence of genetic, environmental and
behavioural factors; the majority of cases are attributable to
excess body weight and sedentary lifestyles.2 Unmanaged, type 2
diabetes is associated with serious microvascular and macro-
vascular complications that can lead to signiﬁcant disability and
premature mortality.3 The cost implications to health systems is
considerable: the total cost of diabetes care in the UK National
Health Service (NHS) was £23.7 billion ($33.8 bn, €27.4 bn) in
2010–11, with a projected annual cost of £39.8 bn ($56.8 bn, €46
bn) by 2035–36.4
The onset of these complications can occur during a latent or
pre-diabetic phase characterised by impaired glucose metabolism
with fasting plasma glucose levels below internationally agreed
thresholds for diabetes. Non-diabetic hyperglycaemia (NDH) is a
high-risk category of developing diabetes and is a term used to
describe pre-diabetic conditions associated with decreased ability
of the body to regulate glucose effectively, such as impaired
glucose regulation (IGR) and impaired fasting glucose and/or
impaired glucose tolerance.5
There is unequivocal evidence that lifestyle interventions can
reduce the risk of developing diabetes.6 When targeted at people
with NDH, lifestyle interventions that promote physical activity,
diet modiﬁcation and weight loss can reduce the risk of diabetes
by 58%.7,8 However, while the use of lifestyle interventions to
prevent diabetes in people with NDH are recommended in
national guidelines, they are usually resource intensive to deliver
and are unlikely to be cost-effective and implementable at scale
across routine settings.9
Identifying cost-effective lifestyle interventions that can be
deployed in routine settings to prevent diabetes in high risk
populations such as those with NDH is therefore a health policy
priority.10 Health coaching that includes modelling behaviour and
goal setting, has emerged as a promising candidate platform that
can support the delivery of effective lifestyle interventions for
people with long term conditions,11 including diabetes12 and
possibly people with NDH.13 With the ﬂexibility of being accessible
by telephone, health coaching can potentially reach a signiﬁcant
proportion of the target population.
It is possible that reach and efﬁciency of telephone health
coaching could be enhanced further by digitally-enabled compo-
nents. The last decade has seen increased use and availability of
second generation web-based interventions that include program
and interactive content, multimedia materials and guidance and
feedback.14 Web-based interventions have been especially used to
promote behaviour change and manage mental health pro-
blems.15,16 And there is good evidence that technology assisted
primary care interventions that combine either the internet,
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personal computer, and/or a mobile device are effective in
supporting people to lose weight.17 Fully automated interventions
that support web-based and mobile facilitated goal setting and
personalised behaviour change have also proven effective in
reducing cardiovascular risk among overweight and obese adults
and in improving glycaemic control and reducing other risk
factors for diabetes, but gains are short-lived.18,19
While there is an emerging consensus about best practice in
developing and evaluating effective web-based interventions,
there is less emphasis on understanding how end-user satisfaction
can inform successful implementation in routine settings.20 In the
context of web-based interventions user satisfaction and experi-
ence ratings are important metrics that go beyond developer
assessments of design and build quality and potentially provide
critical feedback about usability and acceptability relevant to
healthcare providers.21 Satisfaction is increasingly used as an
outcome of interest in evaluations of web-based health interven-
tions and there is growing recognition that satisfaction can
capture user perception of their experience of web-based
interventions.22,23
In the context of the CATFISH trial a telephone-only health
coaching intervention for people with NDH was established as
routine care and the aim of the trial was therefore to compare two
active treatments to determine if a digitally-enabled health
coaching intervention improved user experience and led to
higher efﬁciency. Speciﬁcally the CATFISH trial aims to assess
whether a digitally-enabled telephone coaching intervention
(IGR3) is more acceptable than an existing telephone-only
coaching intervention (IGR2) for people with NDH. Secondary
objectives of the trial are to (1) determine whether the delivery of
the IGR3 intervention is more efﬁcient than the existing
commissioned IGR2 intervention; (2) to explore the cost-
effectiveness of IGR3 in comparison with IGR2; (3) to qualitatively
explore and compare user and provider experience of IGR3 and
IGR2 interventions; and (4) to explore the impact, if any, of IGR3
compared with IGR2 on clinical outcomes relevant to diabetes
prevention in people with NDH
RESULTS
Participant recruitment and retention
Between July 2015 and May 2016 there were 853 referrals from
general practice in Salford to Care Call. Of these 253 (29.7%)
verbally consented to be contacted by the research team at the
University of Manchester about participating in the CATFISH trial.
Of those that consented to be contacted 210 (83%) agreed to take
part in the CATFISH trial and were assessed for eligibility and
invited to a baseline assessment following receipt of their written
informed consent. The ﬁrst participant was recruited on 30th June
2015 and the last participant was recruited on 25th May 2016. One
participant was withdrawn from the trial before allocation because
they were found to have type 2 diabetes. 209 participants were
randomised, with 103 allocated to IGR2 and 106 allocated to IGR3.
87% of participants returned a follow-up questionnaire for the
primary outcome. The ﬂow of participants is shown in Fig. 1.
Baseline characteristics of participants
Participants had a mean age of 58.3 (SD 11.4) years and 44% were
female. The majority (94%) were from white ethnic backgrounds
and just under half (47.5%) were either in full or part-time paid
employment. Participants had a mean HbA1c of 44.4 (SD 1.6)
Assessed for eligibility (n=850)
Excluded  (n=641)
- Not meeting inclusion criteria (n=598)
- Declined to participate (n=34)
- Other reasons (n=9)
Primary outcome analysed  (n=96 )
Excluded from analysis (give reasons) (n=0)
Lost to follow-up (n=7)
- Withdrew (n=3)
- Unable to contact (n=1)
- Declined to be contacted (n=3)
Allocated to intervention (n=103)
- Received allocated intervention (n=103)
- Did not receive allocated intervention
- (give reasons) (n=0)
Lost to follow-up (give reasons) (n=21)
- Died (n=1)
- Withdrew (n=6)
- Unable to be contacted (n=9)
- Declined to be contacted (n=5)
Allocated to intervention (n=106)
- Received allocated intervention (n=80)
- Did not receive allocated intervention
- Switched to IGR2) (n=26)
Primary outcome analysed  (n=85)
- Excluded from analysis (give reasons) (n=0)
Allocation
Analysis
Follow-Up
Randomized (n=209)
Enrollment
Fig. 1 CONSORT ﬂow diagram
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mmol/mol, which is equivalent to 6.2% HbA1c. All participants had
a BMI in the obese range (>30 Kg/m2) at baseline, with a mean BMI
of 33.9 (SD 7.3). Over a quarter (28.2%) of participants met the
threshold on MHI-5 for probable depression at baseline. Partici-
pants in the two groups were similar in all respects, except that a
higher proportion of females were allocated to IGR2 compared
with IGR3 (48.5 vs. 39.6%). Table 1 shows the baseline
characteristics of the participants by treatment allocation.
Intervention uptake and adherence
Seven participants (one allocated to IGR2; six allocated to IGR3)
withdrew before they received an action planning call. A further
10 participants (three allocated to IGR2; seven allocated to IGR3)
did not receive any follow-up calls after the initial action planning
call. Twenty-six participants allocated to IGR3 switched to IGR2
during the course of their exposure to the intervention. Ninety-
nine participants in IGR2 and 93 participants in IGR3 had at least
one follow-up call and the majority of these (73% in IGR2; 64% in
IGR3) had more than ﬁve attempted follow-up calls. The mean
total health advisor contact time per participant was 142.6 (SD
50.7) minutes for IGR2 and 132.2 (SD 66.5) minutes for IGR3.
Outcomes
We collected primary outcome data for 181 (87%) participants.
Missing outcome data were therefore imputed for 28 participants.
At follow-up, the mean score on the CSQ-8 in IGR2 was 27.1 (SD
5.2), and in IGR3 was 28.4 (SD 4.5). Controlling for relevant
covariates, the total score for the CSQ-8 was 1.32 points higher
(95% conﬁdence interval −0.13 to 2.77; p= 0.074) in participants
allocated to IGR3 compared with those allocated to IGR2. This
equates to a small effect size (standardised mean difference 0.29,
95% C.I. −0.01 to 0.58). There is, therefore, weak evidence in
favour of IGR3, but not at the 5% level of signiﬁcance. Both the
per-protocol (CSQ-8 difference= 1.33; 95% C.I. −0.22 to 2.88; p=
0.091) and complete case (CSQ-8 difference= 1.39; 95% C.I. −0.03
to 2.88; p= 0.062) analyses for the primary outcome returned very
similar results to the intention to treat analyses: differences in total
satisfaction scores between IGR2 and IGR3 were not signiﬁcant at
the 5% level.
Secondary outcomes were only analysed and presented for
complete cases (Table 2). While secondary outcomes broadly
favoured IGR3 the differences did not reach signiﬁcance. Only the
between group difference in BMI was borderline signiﬁcant (p=
0.05).
Routine service level data
None available.
Qualitative data
To be reported in a separate process evaluation.
Economic analysis
Intervention delivery and costs. The resources needed to deliver
IGR3 over the 9-month observation period included training Care
Call staff and monthly IT costs (Table 3). Pedometers cost £2.20 per
participant in IGR3. All participants received the Leicester Diabetes
booklet at a cost of £1 per participant. Supervision of health
coaching staff at Care Call cost £200 per participant over 9-months
based on salary rates for 240 h for an Agenda for Change Band 7
manager and 1283 h for an Agenda for Change Band 2
administrator. The average ﬁxed costs per participant were £201
in IGR2 and £439 in IGR3.
The average call time (including administration) for action
planning was slightly higher in IGR3 compared with IGR2. Among
those who had at least one attempted follow-up call the average
call time (including administration) was similar in both groups
(Table 4). Combining the call time (including administration) with
unit costs of staff delivering the interventions, the mean cost of
calls per participant was £144 (SD £44) for IGR2 and £142 (SD £56)
for IGR3, excluding the seven withdrawals before action planning
call attempts.
Cost effectiveness analysis with imputation. Table 5 presents the
adjusted estimates of the incremental costs associated with
delivery of interventions from a CCG perspective. IGR3 is
associated with a mean incremental cost of £236 (95% CI £223
to £250) and a mean ICER of £182 (95% CI £84 to £931) per point
improvement on the CSQ-8. The complete cases analysis showed
a similar incremental costs per participant with a smaller
difference in CSQ-8, leading to a much higher ICER with wider
conﬁdence interval (supplementary material 1).
DISCUSSION
There was no evidence that participants who used a digitally-
enabled telephone coachin intervention that included an online
dashboard plus telephone health coaching for preventing
diabetes were more satisﬁed with their healthcare than partici-
pants who used a telephone only health coaching intervention.
While there was an indication that participants who received the
digital intervention were more activated, had improved health
status and reduced depressive symptoms, the differences
Table 1. Baseline characteristics of participants
IGR2 (n= 103) IGR3 (n= 106)
Mean age 59.0 (11.3) 57.6 (11.6)
Age in categories:
25–44 years 9 (8.7%) 11 (10.3%)
45–64 years 59 (57.3%) 64 (60.4%)
65–84 years 35 (34.0%) 31 (29.2%)
Sex (female) 50 (48.5%) 42 (39.6%)
Ethnicity
White (British/Irish/Other) 97 (94.2%) 99 (93.4%)
Non-White 6 (5.8%) 7 (6.6%)
Economic status
Working full-time 34 (33.3%) 41 (39.4%)
Working part-time 13 (12.7%) 11 (10.6%)
Unemployed 7 (6.9%) 3 (2.9%)
Permanently sick 8 (7.8%) 8 (7.7%)
Retired 34 (33.3%) 32 (30.8%)
Other (F/T Education/Looking after
Home/Something Else)
6 (5.9%) 9 (8.6%
Missing data 1 2
Mean BMI 33.4 (6.7) 34.4 (8.0)
Mean HbA1c (mmol/mol) 44.7 (1.6) 44.2 (1.6)
Mean patient activation (PAM-13) 62.2 (14.3) 60.8 (13.1)
Mean general health VAS 69.3 (19.8) 66.1 (19.9)
Mean MHI score 71.9 (20.8) 70.3 (20.2)
Probable depression diagnosis
Depression 26 (25.2%) 32 (30.2%)
No depression 77 (74.8%) 74 (69.8%)
Note: Data are means (SD) or numbers (%)
BMI body mass index, EQ-5DL EuroQol-5DL, HbA1c Glycated haemoglobin,
MHI Mental health inventory, mmol millimoles per litre, mol mole per litre,
PAM patient activation measure, VAS visual analogue scale
P. Coventry et al.
3
Scripps Research Translational Institute npj Digital Medicine (2019)     5 
compared with participants in the telephone only group were not
signiﬁcant. At follow-up participants in both groups had lower
HbA1c and BMI but the between group difference for these
outcomes was not signiﬁcant. There were no signiﬁcant differ-
ences between the groups for other secondary outcomes. Attrition
was slightly higher in IGR3 and a quarter of participants in this
group switched to IGR2 and received the telephone only
intervention. However the per protocol analysis returned similar
results to the intention-to-treat analysis suggesting that partici-
pants were satisﬁed with the overall health coaching approach
regardless of allocation. Contact time between health coaches and
participants was broadly equivalent in both groups. Although
both were used for less than the maximum of 180 h allotted for
the IGR pathway, IGR3 was not found to improve staff efﬁciency as
expected. From a provider perspective the additional cost of the
digital intervention was £236 ($332; €270) per participant to
deliver, which consisted mostly of the training and platform costs
of the online dashboard.
Previously it has been shown that satisfaction with telephone
only health coaching is associated with higher levels of activation
and number of sessions completed among those enrolled in a
behaviour change programme to prevent diabetes.24 While there
was a signal that participants in IGR3 were more satisﬁed and
more activated than those in IGR2, we cannot be certain this was
associated with the availability of the digitally-enabled interven-
tion. Indeed, because there was no difference in uptake and
number of follow-up telephone coaching calls between the two
Table 2. Complete case analyses of secondary outcomes at 9-months follow-up
IGR2 IGR3
Outcome No of participants Mean (SD) No of participants Mean (SD) Adjusted difference in means (95% CI)a P value
HbA1c (mmol/mol) 77 43.4 (4.2) 70 42.9 (3.2) −0.37 (−1.48 to 0.67) 0.50
BMI (kg/m2) 89 33.8 (6.7) 84 32.4 (7.3) −0.52 (−1.05 to −0.00) 0.05
EQ−5D−5L 53 0.72 (0.3) 58 0.73 (0.2) 0.02 (−0.00 to 0.03) 0.07
General Health VAS (0–100) 96 71.5 (19.4) 84 73.3 (22.1) 2.86 (−2.5 to 7.9) 0.27
MHI (0–100) 94 73.0 (19.7) 85 72.7 (19.9) 0.07 (−4.0 to 4.0) 0.97
PAM score (0–100) 96 64.6 (15.3) 85 65.2 (13.8) 0.78 (−2.9 to 4.4) 0.67
SDSCA
Days ate ≥5 portions of Fruit and
vegetables
95 4.54 (1.7) 85 4.33 (1.9)
Days ate high fat foods 96 4.35 (1.8) 85 4.26 (2.1)
Days participated in ≥30mins
physical activity
102 4.1 (2.2) 85 4.6 (2.1)
Days participate in speciﬁc
exercise session
96 1.2 (1.7) 85 1.2 (1.8)
Days drank alcohol 96 5.4 (2.1) 85 5.6 (1.9)
Cigarettes per day 18 13.6 (7.6) 17 13.0 (7.8)
BMIbody mass index, EQ-5DLEuroQol-5DL, HbA1cglycated haemoglobin, MHImental health inventory, mmolmillimoles per litre, molmole per litre, PAMpatient
activation measure, SDSCAsummary of diabetes self-care activities, VASvisual analogue scale
aAdjusted differences are those reported by the regression models - the average between-group difference, but adjusted for covariates in the model
Table 3. Costs of training and online dashboard to support delivery of
IGR3
Hitachi training (×3 2-h sessions) N Cost
Trainers
IT project manager 1 £300
IT technical manager 1 £225
Service designer 1 £375
Trainees
Care call service manager 1 £312
Diabetes specialist nurse 6 £1512
Health advisor 5 £900
Programme administrator 1 £138
Total training cost £3,762
Training cost per participant in IGR3 £36
Online dashboard costs (per month, including VAT)
Set up and hosting services £930
Server rental £410
Third line support £1020
Total costs over 9 month trial £21,240
Dashboard cost per participant in IGR3 £200
Table 4. Mean time in minutes for delivery of action planning and
follow-up calls over 9-months by allocation group
IGR2 (n= 99) IGR3 (n= 93)
Mean (SD) Range Mean (SD) Range
Action planning call
Pre-call admin 3.8 (2.8) 0–15 5.6 (3.9) 0–24
Call time 28.1 (8.1) 2–47 28.3 (11.0) 5–88
Post call admin 20.1 (7.4) 6–45 21.0 (11.5) 4–76
Total 52.5 (13.7) 13–96 54.9 (20.7) 14–136
Follow-up calls
Pre-call admin 6.6 (3.8) 0.7–20.0 6.8 (4.1) 0.0–20.0
Call time 21.4 (5.4) 11.0–45.5 21.9 (6.5) 4.0–50.0
Post call admin 12.4 (3.8) 5.7–28.0 13.0 (5.2) 5.7–40.0
Total 40.3 (10.2) 25.0–78.0 41.8 (11.4) 20.0–89.0
P. Coventry et al.
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groups, it is still possible that any difference in satisfaction and
activation may be attributed to the quality of health coaching.
While this trial was not set-up as a superiority test for clinical
outcomes, it is instructive to compare before and after results
achieved in CATFISH with those reported in comparable studies
that tested lifestyle interventions for preventing diabetes in
routine practice. In updating the review by Dunkley et al, Public
Health England reported a pooled reduction in HbA1c of 0.07% for
11 pragmatic lifestyle interventions at 12–18 months follow-up.25
A similar result was reported at 6-months for a community based
diabetes prevention programme run along pragmatic lines in the
NHS.26 In CATFISH the overall performance of the IGR Care Call
intervention was associated with a mean reduction in HbA1c of
0.10% with no difference between trial groups. This is equivalent
to results of more intensive national diabetes prevention
programmes such as those run in the United States which
showed a mean reduction in HbA1c of 0.10% at 12 months.8
Similarly, weight loss results for the IGR Care Call interventions
were equivalent or outperformed results from comparable
pragmatic interventions such as Let’s Prevent which reported a
mean difference of 0.11 in BMI scores between the intervention
group and standard care.26 Larger effects were reported by Block
et al who tested the effects of a fully automated digital behaviour
change intervention among people with prediabetes.19 In that
trial participants who used the web-based intervention reported a
mean reduction in HbA1c of 0.26% and a mean reduction of 1.05
in BMI scores at 6-months. While participants were not supported
by face-to-face or telephone coaching they did have access to
social support via online networks and engaged in team based
competitions suggesting that peer support and gamiﬁcation
might be critical to the success of online interventions.
Attrition is typically higher in trials of web-based interventions
compared with controls, with drop-outs reported to be 22.5%.27 In
CATFISH drop out from the web plus telephone group was 24.5%
when withdrawals and those who switched to the telephone only
group are combined. It is clear that therapeutic contact on the
telephone can improve usage and outcomes of web-based
interventions.16 However, unlike other web delivered lifestyle
interventions that used telephone support we did not see a
difference between the two groups in uptake of the telephone
element of health coaching and we do not know if telephone
coaching improved usage of the digital content of the
intervention.28
This was not a cost-effectiveness study but we did assess costs
attributed to the set-up and delivery of the digital intervention.
The higher cost for using IGR3 were mainly associated with the
web elements. The expected effect on efﬁciency was not found in
the trial, which could be a result of lack of integration between the
telephone and digital components. If the digital platform only
served as a notebook, the platform could potentially only add
additional burden associated with the training without any
intended beneﬁt. With no efﬁciency savings gained, it would be
for the provider to judge if the additional cost per point of
improvement on the CSQ-8 is worth paying. A key advantage of
digitally-enabled interventions is that they have potential to reach
economies of scale, which might take place as the user base
grows. Based on modelling used in the digital pilot of the National
Diabetes Prevention Programme in the NHS,29 the digitally-
enabled telehealth intervention designed by Hitachi is purported
to achieve efﬁciencies of scaling over telephone only interventions
at 3000 users per year with the use of cloud based infrastructure
and improved management capacity. In that model the cost of the
digitally-enabled intervention would be £383 per person; a fully
optimised cost basis is achievable at 10000 users per year costing
£309 per person. There is potential to reduce the cost of the
digitally-enabled intervention further with the use of a dynamic
care pathway whereby users are segmented into three categories
of health coaching support. In this dynamic model the cost per
person is proposed to be £326 with a user base of 3000 per year,
and £292 per person with a user base of 10000.
The digital intervention was embedded within an existing
service that was delivered as part of routine care for people with
NDH and in this sense the CATFISH trial responds to the need to
address the translational gap between evidence and practice in
diabetes prevention.30 Additionally the CATFISH trial evaluated
end-user satisfaction as a primary outcome and thereby under-
scores the importance of assessing patient experience of
interventions.31 As with most trials there is the possibility that
we only reached and included a self-selecting cohort of eligible
patients and that this group were the most motivated to engage
with the intervention. However, participants were blind to
treatment allocation and were not aware which intervention was
novel; researchers and analysts were also blind to treatment
allocation. Finally, drop outs from IGR3, including those who
switched to IGR2, was moderately high but we do not know the
reasons for this, nor do we know why once engaged in health
coaching participants completed their call schedules. These
questions will partly be addressed in a separate qualitative
process evaluation.
In the context of continued roll out of diabetes prevention
programmes, such as that launched by NHS England, it is
important to recognise that relatively low intensity interventions
such as the ones deployed in CATFISH have an important role to
play in translating evidence into practice.32 Encouraging patients
to engage with digital health interventions is a challenge and their
reach and scaling are likely to hinge on successful outreach and
enrolment activities.33 Where digital interventions are preferred it
is critical that inclusion is enhanced to contend with higher rates
Table 5. Cost-effectiveness analysis from clinical commissioning group perspective
Costs/outcomes IGR2 (N= 103) IGR3 (N= 106)
Cost of training, managing and other materials (mean, SE) £201 (£0) £439 (£0)
Cost of calls made within 9 months period (mean, SE) £144 (£4) £141 (£6)
Total intervention costs (mean, SE) £345 (£4) £581 (£6)
Unadjusted difference in intervention costs (mean, 95% CI) £236 (£222 - £250))
Adjusted difference in intervention costsa (mean, 95% CI) £236 (£223 - £250)
CSQ-8 score (mean, SE) 27.1 (0.5) 28.5 (0.5)
Unadjusted difference in CSQ-8 score (mean, (95% CI) 1.3 (0.1–2.5)
Adjusted difference in CSQ-8 scorea (mean, 95% CI) 1.3 (0.1–2.5)
ICER (mean, 95% CI) £182 (£84 - £931) per point improvement on CSQ-8
CI conﬁdence interval, ICER incremental cost-effectiveness ratio, SE standard error
aadjusted for age and gender
P. Coventry et al.
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of digital exclusion among the most deprived and among those
who lack the conﬁdence and skills to use online approaches.34 As
with other digital interventions there is also need to consider how
to maximise adherence and optimise usage and the use of games
and SMS alerts, as well as improving accessibility on mobile
platforms are possible avenues for further evaluation. Critical too
is the need for a better understanding of the optimal combina-
tions of behaviour change techniques and mode of delivery for
web-based interventions. A review of 52 online health interven-
tions showed that only usability was associated with effectiveness,
but there was little evidence that pointed to the most effective
combinations of behaviour change techniques.35 Component
network meta-analysis is a relatively new approach to meta-
analysis that can unpick the treatment effects of different
components includes in complex composite interventions.36 There
is scope for further elaboration of the most effective combinations
of components for web-based behaviour change interventions
using this approach. Deﬁnitive testing of candidate interventions
would further enhance the evidence base for web-based
behaviour change and health promotion interventions.
We showed that user satisfaction and experience of a digital-
enabled telephone coaching intervention that included an online
dashboard and telephone health coaching was broadly equivalent
to that of a routinely delivered telephone-only coaching
intervention for people with NDH. On the basis of user satisfaction
there is scope to consider this digitally-enabled telephone
coaching intervention as an option for decision makers with
responsibility for commissioning diabetes prevention services.
However there is still uncertainty about cost-effectiveness of this
digitally-enabled telephone coaching intervention and further
deﬁnitive evaluation is warranted. Furthermore, future work is
needed to assess whether economies of scale are achievable
outside the context of trial based evaluations where user bases are
likely to be much larger.
METHODS
Study design and participants
CATFISH was an individually randomised controlled trial conducted at the
Salford NDH Care Call (previously known as IGR Care Call) service provided
by Salford Royal NHS Foundation Trust, Greater Manchester. The trial
protocol has been previously published.37 Ethical approval was granted by
NHS Research Ethics Committee for the East of England (Cambridgeshire
and Hertfordshire) (reference no 15/EE/0117).
Participants for CATFISH were identiﬁed from referrals from primary care
or community teams to NDH Care Call. Referral criteria to NDH Care Call
were: moderate or high risk on the Leicester Diabetes Risk Score
Assessment Tool38 and HbA1c= 42–47mmol/mol (6.0–6.4%) or a previous
diagnosis of IGR with 1x conﬁrmatory blood test (HbA1c within the
previous 6 months).
Additional eligibility criteria for inclusion in CATFISH were adults aged
>18 years and access to a telephone and home internet. We excluded
people with a diagnosis of type 2 diabetes (HbA1c of ≥ 48mmol/mol
[≥6.5%]); a diagnosis of gestational diabetes; did not read or speak English;
and those incapable of participating as indicated by their GP because of
dementia, learning difﬁculties, vision or motor skills limitations, serious and
enduring mental health problems.
Randomisation and masking
Contact details of eligible patients were forwarded to the Care Call
programme administrator who asked whether patients were willing to
discuss participation in the CATFISH trial. Patients who verbally consented
to be contacted about CATFISH were then telephoned by the research
team (AB and EB) who checked their eligibility for the trial and invited
them to agree to a baseline assessment. Once signed consent forms had
been received and the baseline assessment had been completed
participants were randomised using a central randomisation service
provided by the Manchester Academic Health Science Clinical Trials Unit
at the Christie NHS Foundation Trust. Participants were allocated 1:1 by
minimisation using BMI and HbA1c at baseline. This technique ensures that
treatment groups are very closely similar for several variables, even in small
samples.39 The principal investigator and NDH programme administrator
were aware of allocations; research staff and analysts were blinded to
allocation. Treatment allocation was concealed from participants at the
baseline assessment appointment. It was not possible to blind the health
professionals delivering the interventions.
Interventions
The telephone only service was known as IGR2. The digitally-enabled
telephone service was known as IGR3. The service speciﬁcation was
adapted from the Diabetes Care Call service and a previously piloted
6 month telephone delivered lifestyle and education programme for
people with impaired glucose tolerance.12,40,41 The core content for both
IGR2 and IGR3 includes education about reducing the risk of developing
diabetes, goal setting and action planning, and coaching from health
advisors to support patients to achieve their goals and to maintain and
review their action plans. Health advisors are NHS Agenda for Change
band 4 workers who received at least two months in-house induction
training that included the X-pert 6-week diabetes patient education
programme which includes education sessions about the prevention of
diabetes, and education sessions for newly diagnosed type 2 diabetes
patients and insulin starters.42 Additionally all advisors completed a 1-day
training course in motivational interviewing provided by Advancing
Quality Alliance and delivered by an independent training company.43
Advisors were also given educational materials, took part in telephone
role-play calls, observed diabetes clinics, attended medication training with
the Diabetes Team, and shadowed calls from trained advisors.
The telephone schedule was similar for IGR2 and IGR3 and comprised an
introductory call from the programme administrator, followed by a
30–40min action planning phone call from a diabetes specialist nurse or
dietician [call 1]; 6 × 10–20min phone calls over six months from the
health advisor [calls 2–7]; and a ﬁnal step-down 10–20min call at nine
months [call 8]. All calls were outbound and heath advisors maintained
contact with the same patients throughout the care pathway.
Before the action planning call all participants received a copy of the
Leicester diabetes booklet. Participants completed ‘My Plan’ which helped
them to reﬂect on how they might make changes to their food choices and
activity to manage their risk of diabetes. The action planning call was not
scripted and focused on explaining the signiﬁcance of blood tests results,
understanding risk factors for diabetes, exploring participants’ readiness to
change and encouraging them to identify SMART goals. Weight loss
targets of 5 and 10% were communicated to the participants. The six
follow-up calls were guided by scripts modelled on those used by Diabetes
Care Call but with an emphasis on diet and exercise and tailoring to ensure
that call content was patient-centred and ﬂexible to support their
individual goals. The step-down call at 9 months provided an opportunity
to negotiate and agree onward action plans and discharge participants
back to GP care.
The critical innovation in IGR3 was the addition of an online dashboard
that was accessible by participants and health advisors. The dashboard was
co-designed with patient groups and front-line NHS Health Advisors, based
on both Hitachi’s experience of delivering diabetes prevention and well-
being programmes in Japan and SRFT experience of developing and
delivering a telehealth diabetes prevention programme known as Diabetes
Care Call.12 The dashboard was designed for use on desktop computers
only. The patient view included an interactive and dynamic log that
enabled participants to track their progress against action plans and
monitor their weight, physical activity, and blood glucose. Additionally the
dashboard view included a space for participants to message health
advisors and a progress tracker to identify completed and future call
events (Supplementary 2).
Before the action planning call, the participants allocated to IGR3 were
sent a pedometer to log their activity during the six months exposure to
the intervention. Participants allocated to IGR3 also completed an online
self-assessment before the action planning call. The IGR3 care pathway was
supported by three embedded videos on the online dashboard:
Introduction; Guide to Self-Assessment; Guide to the Dashboard (supple-
mentary 3). Health advisors could access logged information to assess the
progress of the participants and tailor the follow-up calls accordingly.
Primary outcome
The primary outcome was the mean difference in total score of the Client
Satisfaction Questionnaire (CSQ-8)44 at 9 months post-randomisation. This
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end point was chosen to coincide with the timing of the scheduled step-
down call. The CSQ-8 is an 8-item generic survey instrument used in
primary care clinical trials and has been widely used as a measure of user
satisfaction of web-based interventions.45 It is scored using a four-point
Likert with a range from 8 to 32; higher scores indicate higher satisfaction.
The CSQ-8 was measured only at follow-up with computed scores used to
calculate the mean difference between groups.
Secondary outcomes
HbA1c concentration. Glycated haemoglobin (HbA1c) was measured with
a blood test taken from participants after the step-down call at the Barnes
Clinical Research Facility, SRFT. Sample type and volume used were
ﬂuoride oxalate (yellow), 1 mL; reference range and units were 3.0 to
6.0 mmol/L. Participants who declined a blood test at follow-up were asked
to consent to sharing the results of routine blood tests taken at their
general practice. HbA1c represents average blood glucose over a 8 to
12 week period.46 We used routine test results that were reported between
12 weeks before or 12 weeks after the end of follow-up.
BMI. BMI (kg/m2) was measured using height (m) taken at baseline and
weight (kg) measured at follow-up using ISO 9001:2008 standard scales
(Seca model 8751) that were calibrated using weights traceable to the
National Physics Laboratory Standards of Mass.
Quality of life. The ﬁve-item EQ-5D-5L is a generic measure of health-
related quality of life consisting of the EQ-5D descriptive system and EQ
Visual Analogue Scale (EQ VAS).47 The ﬁrst part consists of 5 domains:
mobility, self-management, ability to do usual activities, pain, anxiety and
depression, with 5 levels of severity for each domain (no, slight, moderate,
severe, and extreme problems). The VAS records an individual’s perceived
self-rated health, ranging from 0 to 100; higher values indicate better
general health. The EQ-5D-5L was used at baseline and follow-up.
Mental health. The Mental Health Inventory (MHI-5) is a 5-item scale
which measures general mental health, including depression, anxiety,
behavioural-emotional control and general positive affect.48 We used the
recommended score ≤ 60 (high scores on this scale represent greater well-
being) to indicate the presence of ‘probable depression’;49 continuous
scores were used in the analysis. The MHI-5 was collected at baseline and
at follow-up.
Health experience and self-management. We evaluated self-management
behaviours using the revised version of the Summary of Diabetes Self-Care
Activities (SDSCA) scale.50 The SDSCA includes items that assess diabetes
self-management across core domains related to: general diet, speciﬁc
diet, exercise, blood-glucose testing, foot care, and smoking. We used
items relevant to diabetes prevention and assessed the number of days
per week participants engaged in healthy and unhealthy behaviours (i.e.,
eating ≥5 portions of fruit and vegetables; eating high fat food;
participating in ≥30min of physical activity; participating in speciﬁc a
speciﬁc exercise session; drinking alcohol). We also included an item on
number of cigarettes smoked per day. Health experience and self-
management data were collected at baseline and at follow-up.
Patient activation. The Patient Activation Measure (PAM)−13 is a self-
report measure of patient knowledge, skills and conﬁdence in self-
management for long-term conditions.51 We used the short 13 item
version.52 The score (0–100) can be used to segment patient populations
into four levels of activation but we used the continuous score in the
analysis. The PAM-13 was collected at baseline and at follow-up.
Statistical analysis
We powered the study to have 90% power (with a 2-sided alpha level of
5%) to detect a standardised effect size of 0.5 on the CSQ-8. Allowing for a
15% attrition rate, 200 participants were needed in total (100 per group).
Basic summary statistics (mean, SD, minimum, maximum) were calculated,
by trial group, for each of our primary and secondary outcome variables.
For the CSQ-8, data were only available at follow-up, whereas for all other
outcomes, data were available at both baseline and follow-up. In order to
formally test for post-intervention differences between CSQ-8 scores in the
two groups, we conducted linear regression analysis, controlling for
participant age-group, gender and baseline measurements of BMI, HbA1c,
Patient Activation, MHI-5 and self-rated general health status. The primary
analysis was conducted following the intention-to-treat principle. The CSQ-
8 was only available for 181 observations whereas between 179 and 181
observations were available for secondary outcomes. The missing data in
the outcome and covariates were handled by multiple imputation using
chained equations, with 20 replications. To ease interpretation and to allow
comparison with published studies, we estimated a standard effect size
(Cohen’s d) for the CSQ-8 as the difference in follow-up means divided by
the pooled baseline standard deviation for all participants. Missing data for
secondary outcomes were not imputed but presented in available cases
(Table 2). A per-protocol approach that analysed participants based on
ﬁnal treatment destination was used as a sensitivity analysis, again using
the same multiple imputation approach as in the primary analysis. A
secondary, complete-case, analysis was also conducted; here, we derived
percentile-based, bootstrapped standard errors using 10,000 replications.
Analyses were conducted using Stata Statistical Software: Release 15.
Health economic analysis
The health economic analysis aimed to identify and measure the cost and
beneﬁts of delivering IGR2 and IGR3. The primary analysis was conducted
from a Clinical Commissioning Perspective (CCG) perspective using
intervention costs and the CSQ-8 to derive an additional cost per
additional point of the CSQ-8. CCGs are clinically-led statutory NHS bodies
responsible for the planning and commissioning of health care services for
their local area. All costs were presented in UK pounds Sterling (£) for the
ﬁnancial year 2015–16. Costs were inﬂated to 2015–16 price levels where
necessary using the Hospital and Community Health Services pay and price
inﬂation index.53 No discount rate was applied to either costs or
effectiveness because the follow-up period was 9 months.
Intervention costs. A micro-costing exercise was conducted following the
methods of technology appraisal recommended by NICE.54 Training to
support delivery of IGR3 was provided by Hitachi. It consisted of three 2-h
sessions conducted by the IT project manager, IT technical manager and
service designer. The Care Call service manager, programme administrator,
six diabetes specialist nurses/diabetic dieticians and ﬁve health advisors
attended the training. The cost of development of IGR3 platform was
considered a ‘sunk cost’ and therefore not included.55 The total costs of the
training were evenly allocated to the IGR3 participants.
The online dashboard was costed for the 9 months intervention period
using contract pricing provided by Hitachi. This included monthly costs for
set up and hosting services, server rental and third line support, including
VAT. These ﬁxed costs were evenly allocated to each participant in IGR3.
Unit costs of staff delivering both IGR2 and IGR3 were based on
estimates of costs of health and social care compiled by the Personal Social
Services Research Unit (PSSRU)53 (supplementary material 4). These unit
costs were then multiplied by the time spent recorded in the call log or
timesheet during the trial period to estimate the costs of delivering the
interventions.
Cost-effectiveness. Incremental cost-effectiveness analysis combined the
intervention costs with the primary outcome to generate an incremental
cost-effectiveness ratio (ICER), by dividing the mean difference in costs
between the two trial groups by the mean difference in effect.56 From a
CCG perspective the ICER was interpreted as the additional intervention
cost per participant for one point improvement on CSQ-8.
Missing data were handled by multiple imputation following Rubin’s
rules,57 assuming that any missing data were missing at random. A chained
equation model was developed and predictive mean matching by
intervention groups was used as the imputation method, using the ten
nearest neighbours to the prediction as a set to draw from. The number of
imputations was set to approximately the highest percentage of missing
data in all variables included in the imputation model.58 Due to the non-
normal distribution of both cost and outcome data, 5000 replacement
samplings were generated using bootstrap technique to derive 95%
conﬁdence intervals. A sensitivity analysis was undertaken to repeat the
CEA using complete cases.
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